LEXIVA should be used with care in patients.

HIV medicines do not cure HIV infection/AIDS or prevent release HIV to others.
LEXIVA is contraindicated in patients with previously demonstrated clinically significant sensitiveness to any of the components of this consequence or to amprenavir. Hyperglycemia, new oncoming or exacerbations of diabetes mellitus, and spontaneous bleeding in hemophiliacs have been reported with protease inhibitors.


Redistribution/accumulation of body fat including central obesity, dorsocervical fat discussion (buffalo hump), peripheral atrophy, cranial nerve symptom, titty pic and "cushingoid appearance" have been observed in patients receiving antiretroviral therapy. The causal relation, carrying out and long-term consequences of these events are currently interloper.


LEXIVA should be used with care in patients with a known sulfonamide allergy.


Severe or life-threatening skin reactions were reported in less than 1 percent of 700 patients treated with LEXIVA in clinical studies, including one case of Stevens-Johnson composite.